Abstract: The present invention relates to a novel fulvene compound and a preparation method thereof, and more particularly to a fulvene compound having substituted groups in the 2- and 5-positions, prepared from an unsaturated ketone having a substituted group in the ?-position and a halogen atom in the ?-position, and a preparation method thereof. The present invention also relates to a metallocene catalyst having a substituted group in the ?-position carbon of the bridge of the cyclopentadienyl group only by reaction of a fulvene compound and an anion group including the cyclopentadienyl group, and a preparation method of a polyolefin copolymer using the same.

Abstract: The present invention discloses processes for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates.

Abstract: The invention provides a non-aqueous electrolyte including: at least one kind selected from the compounds represented by Chemical formula 1: wherein R1 and R2 each represent a hydrogen group, a hydrocarbon group or an alkylsilyl group, or any of these groups part or all of the hydrogen atoms of which is/are substituted with a halogen, R1 and R2 may be bonded to each other, and n is an integer of 1 or larger.

Abstract: This invention relates to campholenic derivatives of general formula (I) Wherein R1, R2, R3, R4 and R5 represent, each independently, a hydrogen atom or a linear or branched C1-C5 alkyl or C2-C5 alkenyl group, Y represents a CN, a C(O)R6 or a CR6(OR?) (OR?) group, wherein R6 represents a hydrogen atom or a linear or branched C1-C5 alkyl or C2-C5 alkenyl group, and R? and R? represent simultaneously a linear or branched C1, C2, C3, C4 or C5 alkyl or C2, C3, C4 or C5 alkenyl group and can form together a cycle, the 5-membered ring is saturated or has a double bond between C3? and C4? in formula (I), and the side chain, optionally, has a double bond between C1 and C2 and/or between C3 and C4, provided that the derivative is not 3-methyl-6-(2,2,3-trimethyl-cyclopent-3-enyl)-hex-4-enal; and their use as fragrant or flavouring agent.

Abstract: The present invention relates to substituted cyclopentanone derivatives and their use as fragrance chemicals suitable for incorporation in fine fragrances, cosmetics, toiletries and related applications.

Abstract: The present invention provides a new method for manufacturing a prostaglandin analogue having one or more keto groups on the 5-membered ring and/or omega chain, which comprises the step of treating a corresponding hydroxyl group containing compound with a co-oxidizer under the presence of a tetramethylpyperidine-1-oxyl derivative to form the desired prostaglandin analogue. The method of the invention can be carried out easily under relatively mild conditions.

Abstract: The present invention relates to a novel fulvene compound and a preparation method thereof, and more particularly to a fulvene compound having substituted groups in the 2- and 5-positions, prepared from an unsaturated ketone having a substituted group in the ?-position and a halogen atom in the ?-position, and a preparation method thereof. The present invention also relates to a metallocene catalyst having a substituted group in the ?-position carbon of the bridge of the cyclopentadienyl group only by reaction of a fulvene compound and an anion group including the cyclopentadienyl group, and a preparation method of a polyolefin copolymer using the same.

Abstract: The present invention relates to a cycloalkanone composition which contains cycloalkanone (1) in an amount of 70 wt % or more based on the composition, wherein the content of a dimer of a cycloalkanone represented by formula (2) is 0.055 or less in terms of weight ratio to the cycloalkanone (1), a process for producing the same, a process for producing a composition containing alkyl acetate (5) by using the cycloalkanone composition, and an alkyl acetate composition obtained by the process wherein n is an integer of 1 or 2, R1 and R2 each represent H, a C1 to C8 alkyl group etc., and R3 represents a C1 to C3 alkyl group.

Abstract: A compound of formula (I) or (II): wherein A is hydrogen or CR1R2; Y and Z are each, independently, hydrogen or a halogen; X is —NR4R5, or R7; R1 is hydrogen, or a substituted or unsubstituted alkyl or alkenyl group containing 1–4 carbon atoms; when X is —NR4R5, R2 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1–12 carbon atoms; when X is R7, R2 is an unsubstituted alkyl, alkenyl or alkynyl group, or a substituted or unsubstituted aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1–12 carbon atoms; R3 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1–12 carbon atoms; R4 is hydrogen, a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl

Abstract: There are provided a method of simply preparing a 1,4,6-substituted, 1,4-substituted, 1,6-substituted, or 1-substituted fulvene compound, the intermediates of the fulvene compound, and a method of preparing an ansa-metallocene compound in which two cyclopentadienyl ligands are bridged by one carbon and there are substituents only at positions adjacent to the bridging point of a cyclopentadienyl ligand, using the fulvene compound.

Abstract: The compound according to the formula set forth below and the use of the compound in creating fragrances, and scents in items such as perfumes, colognes and personal care products is disclosed.

Abstract: The present invention relates to substituted cyclopentanone derivatives and their use as fragrance chemicals suitable for incorporation in fine fragrances, cosmetics, toiletries and related applications.

Abstract: Compounds and methods useful in the control, treatment, and prevention of fungal activity, of the following formula: where R1-3 are independently H, alkyl, methyl, acyl, halogen, phenyl, R4 is H, alkyl, methyl, acyl, alkoxy, halogen, phenyl provided that when R3 is methyl and R4 is H, R1 and R2 are not both H; and stereoisomers, analogs, and pharmaceutically acceptable salts thereof.

Abstract: 3-(methoxymethyl)-2-pentylcyclopent derivative compounds having the structure set forth below are disclosed: where: the dotted line represents a potential double bond; R is selected from methyl and ethyl; and X is a C1–C7 hydrocarbon moiety. These compounds are useful fragrance chemicals, suitable for use in creating fragrances and scents in items such as perfumes, colognes and personal care products.

Abstract: The invention concerns a novel compounds of formula (I), wherein the dotted line bond is present or not, and wherein R1 represents: when the dotted line bond is present —CHCH3OH or —CHCH3OCOR or —CHCH3XCH2CHOHR? or —CHCH3OCHR?CH2OH or formula (II) when the dotted line bond is absent —CHCH3OH or —CHCH3OCOR or —COCH3 or formula (II) or —CHCH3XCH2CHOHR? or —CH2CH2XCH2CHOHR? or —CHCH3OCHR?CH2OH or —CHCHCOR? or —CH2CH2CHR?OH or —CH2CH2CHR?OCOR or CHCHCHOHR? or —CHCHCHR?OCOR, wherein R represents H, Me, Et, Pr, isoPr, But, isoBut, CH3CH2)4, (CH3)2CHCH2, CH2CH, (CH3)2CCH, and R? represents H, Me or Et, and X represents O, N or S, and their preparation method. Because of their fragrance, said compounds are highly interesting for the perfume industry, for cosmetic and care products.

Abstract: An excellent fragrance compound having high palatability. A 3-(3-hexenyl)-2-cyclopentenone represented by a general formula (1) (wherein wavy line represents a double bond cis-form and/or trans-form) is used as an active ingredient of scent and mixed in a small amount with fragrance compositions, cis-jasmone and/or various materials to be scented. Since the above compound has a characteristic fragrance quality and high palatability, it is markedly useful as a scenting component of various fragrances and cosmetics, sanitation materials and the like.

Abstract: One aspect of the present invention relates to methods for the transition-metal-catalyzed asymmetric 1,4-addition of a nucleophile, e.g., hydride, to cyclic and acyclic enoates and enones. In certain embodiments of the methods of the present invention, the transition metal catalyst consists essentially of copper and an asymmetric bidentate bisphosphine ligand.

Abstract: The present invention provides a method of synthesizing compounds of formula (I) or (II): wherein R1 is hydrogen, R′ is (C1-C4)alkyl and X is a hydroxyl protecting group.

Abstract: 2-Cyclopenten-1-one and its derivatives comprising the cyclopentenone nucleus as inhibitors of the NF-kB factor, with anti-inflammatory, anti-proliferative-immuno-suppressive, cytoprotective and antiviral activity, the substituents being selected among the ones which do not affect NF-kB inhibitory activity.

Abstract: The compound according to the formula set forth below where A is B is or A and B together form the ring structure and X, R′ and R are independently H and CH3 and m=0 or 1. and the use of the compound in creating fragrances, and scents in items such as perfumes, colognes and personal care products is disclosed.

Abstract: Carbonyl compounds derived from the reaction of alkyl cyclopentenols and vinyl ethers are described. The carbonyl compounds described have excellent fragrance properties, and their use as fragrances and/or fragrance-enhancing compounds is also described. Processes for the preparation of the carbonyl compounds are described as well.

Abstract: This invention describes heretofore unknown forms of dihydro (DHIA) and hexahydro (HHIA) isoalpha acids having a high ratio of trans to cis isomers and a process for their production. Also, non-precipitating clear 5, 10, 20% and higher aqueous solutions thereof, since they are soluble at room temperature in soft water. This is due to the high ratio of trans to cis isomers. Unlike prior art essentially all cis isomer products, they remain haze free both at a neutral pH in water and at 1% to 2% and higher concentrations. This invention has the advantage over the prior art in that DHIA and HHIA can be provided as stable, non-separating liquids, at practical concentrations in the range of 5% to about 40%, which do not require heating to about 50° to 90° C. and above with stirring to effect dissolution of precipitates. The high trans products described herein can be admixed with isoalpha- and tetrahydro-isoalpha acids.

Abstract: The invention deals with the derivatives of benzilidine having basic formula as follows (I): wherein X can be cyclohexanone, cyclopentanone, or acetone, while Y and Z can be either electron withdrawing, electron donating or steric group. Y may or may not be the same with Z. Methyl, ethyl, methoxy group or halogen were prefered in the experiment. The benzilidine cyclohexanone, benzilidine cyclopentanone, and benzilidine acetone derivates were found to be novel compounds showing anti-bacterial, antioxidant, and anti-inflammatory activities that enable them to be used for drug.

Abstract: An improved method is described for making 9-deoxy-PGF1-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.

Abstract: The compound according to the formula set forth below 1

Abstract: The present invention provides a simplified and convenient process for the preparation of an optically active enone such as 7,7-dimethyl-6,8-dioxabicyclo-[3,3,0]oct-3-en-2-one. The invention further provides novel optically active intermediate compounds.

Abstract: One aspect of the present invention relates to methods for the transition-metal-catalyzed asymmetric 1,4-addition of a nucleophile, e.g., hydride, to cyclic and acyclic enoates and enones. In certain embodiments of the methods of the present invention, the transition metal catalyst consists essentially of copper and an asymmetric bidentate bisphosphine ligand.

Abstract: 2-Cyclopenten-1-one and its derivatives comprising the cyclopentenone nucleus as inhibitors of the NF-kB factor, with anti-inflammatory, anti-proliferative, immunosuppressive, cytoprotective and antiviral activity, the substituents being selected among the ones which do not affect the NF-kB inhibitory activity.

Abstract: The present invention relates to a method for opening potassium channels in mammalian cells by administering to a mammal effective amounts of potassium channel-opening keto compounds as described herein.

Abstract: An improved method is described for making 9-deoxy-PGF1-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.

Abstract: 2-Cyclopenten-1-one and its derivatives comprising the cyclopentenone nucleus as inhibitors of the NF-kB factor, with anti-inflammatory, anti-proliferative, immunosuppressive, cytoprotective and antiviral activity, the substituents being selected among the ones which do not affect the NF-kB inhibitory activity. Further the cyclopentenone derivative is a cyclopentenone compound which does not have two adjacent aliphatic side chains or a prostaglandin.

Abstract: 5-Membered ring compounds represented by general formula (I), optically active isomers thereof or salts of the same. These compounds have physiological activities including a carcinostatic effect. In said formula the bond shown by the dotted line in the 5-membered ring represents that this 5-membered ring may be either a cyclopentene ring having a double bond or a saturated cyclopentane ring, and when the 5-membered ring is a cyclopentene ring, X is OR1, Y is ═O and Z is H, and when it is a cyclopentane ring, X is ═O, Y is OR2 and Z is OR3, (wherein R1 is R4 or —(CO)—R5; R2 is H, —R6 or —(CO)—R7; and R3 is H, R8 or (CO)—R9 (wherein R4, R5, R6, R7, R8 and R9 are the same or different and each represents an aliphatic, aromatic or aliphatic aromatic group, and R5, R7 and R9 may be each H), provided that the case where R2═R3═H is excluded); and W represents a residue obtained by eliminating SH from an SH-containing compound.

Abstract: The present invention provides a novel compound represented by the general formula I; wherein R is H or COR3; R1 is H, R2, phenyl, or COR3, wherein R2 is C1-C5 lower alkyl and R3 is R2 or phenyl; Z is CH2 or O; Y is OH, OCOR3 or ═O; x is 0 or 1; and X is C1-C5 n-alkyl, C3-C7 cycloalkyl, phenyl, furanyl, thienyl or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR42, CO2R4 and OR4 wherein R4 is hydrogen or C1-C5 alkyl and dotted lines represent the presence or absence of a double bond and wavy lines represent a cis or trans bond. These novel compounds are especially useful for treating elevated intraocular pressure (ocular hypertension) and glaucoma.

Abstract: Crystals of trans-4,5-dihydroxy-2-cyclopenten-1-one of an &agr;-type.

Abstract: A compound of the formula: wherein R1 and R2 each represents a lower alkyl, or R1 and R2 may be bonded together to form a ring; X represents a spacer of which the number of atoms constituting the principal chain is 1 to 15; Y represents an acyl, or a hydroxy, an amino or an aromatic group, each of which may be substituted; and ring A represents a 5- to 8-membered ring which may be further substituted apart from —X—Y, or a salt thereof is useful as a pharmaceutical composition for preventing or treating disease related to mitochondrial dysfunction.

Abstract: An anticancer agent in which 4-cyclopentene-1,3-dione represented by the following formula [I] and/or 4-hydroxy-2-cyclopentenone represented by the following formula [II] are/is effective component(s).

Abstract: A process for the selective enzymatic hydroxylation of aldehydes and ketones using chiral anchor-protective groups.

Abstract: This invention relates to trimethylsilyloxy-cyclopentane derivatives: 3-(1-Acetoxy-1-methylethyl)- 2-formyl-1-methyl-1-trimethylsilyloxy-cyclopentane; 4-[5-(1-Hydroxy-1-methylethyl)-2-methyl-2-trimethylsilyloxy-cyclopentyl]-3-buten-2-one; 5-[5-(1-Hydroxy-1-methylethyl)-2-methyl-2-trimethylsilyloxy-cyclopentyl]-3-methyl-penta-1,4-dien-3-ol and alkyl 5-[5-(1-Hydroxy-1-methylethyl)-2-methyl-2-trimethylsilyloxy-cyclopentyl]-3-methyl-penta-2,4-dienoates.

Abstract: The preparation of carbonyl compounds by oxidizing a nitro functional group of an organic compound is described. Oxidation is accomplished under catalyzed oxidative Nef reaction conditions.

Abstract: The invention relates to a process for converting alpha acid and isoalpha acids to tetrahydroisoalpha acid. The process comprises isomerizing an alpha acid to produce isoalpha acid and hydrogenating the isoalpha acid in the presence of a noble metal catalyst wherein, the noble metal catalyst is added incrementally or continuously throughout the hydrogenation step. The invention also relates to tetrahydroisoalpha acids made by the above process.

Abstract: The present invention relates to new &agr;,&bgr;-unsaturated ketones of formula I. The new compounds exhibit an intense, very long lasting green galbanum-type odor with fruity undertones. Compositions containing these novel compounds are also provided.

Abstract: 2,3,4-trihydroxycyclopentanone represented by the following formula [I], its optically active substance or salt thereof.

Abstract: The present invention provides a method of synthesizing compounds of ##STR1## wherein R and R' are independently (C.sub.1 -C.sub.4)alkyl.

Abstract: The invention relates to novel substituted cycloalkenes of the formula (I), ##STR1## to a plurality of processes for their preparation, and to novel intermediates and a plurality of processes for their preparation.

Abstract: Spirocyclic compounds of the general formula (I) are provided which are powerful odorants. Compositions which include these compounds are also provided. They can be used, for instance, in perfumery.

Abstract: A .omega.-cycloalkyl-prostaglandin E.sub.2 derivatives of the formula (I) ##STR1## wherein R is carboxy or hydroxymethyl; R.sup.1 is oxo, methylene or halogen atom; R.sup.2 is H, OH or C1-4 alkoxy; R.sup.3 is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by 1-3 of substituent selected from halogen atom, C1-4 alkoxy, C3-7 cycloalkyl, phenyl, or phenyl substituted by 1-3 of substituent selected from halogen atom, C1-4 alkyl, C1-4 alkoxy, nitro, trifluoromethyl; n is 0-4; and non-toxic salt thereof, prodrug thereof and cyclodextrin clathrate thereof can strongly bind on EP.sub.2 subtype receptor. Therefore, they are useful for prevention and/or treatment of immune disease (autoimmune disease, organ transplantation, etc.), asthma, abnormal bone formation, neuron cell death, liver damage, abortion, premature birth or retina neuropathy of glaucoma etc.

Abstract: A cyclopentenone derivative represented by the following formula [I] or an optically active substance or a salt thereof. ##STR1## (In the formula, R.sub.1 and R.sub.2 are same or different and each of them is straight or branched alkyl group, straight or branched alkenyl group, aromatic group, aromatic-aliphatic group or H with a proviso that the case where R.sub.1 =R.sub.2 =H, or R.sub.1 =benzyl group and R.sub.2 =H is excluded.

Abstract: There is disclosed a method of manufacturing 4,5-dihydroxy-2-cyclopenten-1-one represented by the following formula [1] which is characterized in that at least one substance selected from the following (a), (b) and (c) is heated.(a): uronic acid or uronic acid derivative(s);(b): a saccharide compound which contains uronic acid and/or uronic acid derivative(s); and(c): a substance containing a saccharide compound which contains uronic acid and/or uronic acid derivative(s).

Abstract: This invention is concerned with the synthesis of 3-(1-acetoxy-1-methylethyl)-6-oxo-heptanal; 3-(1-acetoxy-1-methylethyl)-2-formyl-1-methyl-cyclopentanol; 5-[2-hydroxy-5-(1-hydroxy-1-methylethyl)-2-methyl-2-cyclopentyl]-3-methyl- penta-2,4-dien-1-ol and 2,7,11-trimethyl-13-[2-hydroxy-5-(1-hydroxy-1-methylethyl)-2-methyl-cyclop entyl]-trideca-2,4,6,8,10,12-hexaenal which are useful as intermediates for the synthesis of lycopene metabolites.

Abstract: A substituted cyclopentene derivative of formula (V): whereinX.sup.1 is (.alpha.-OZ.sup.a, .beta.-H) or (.alpha.-H, .beta.-OZ.sup.a), X.sup.3 is (.alpha.-OZ.sup.d, .beta.-H), (.alpha.-H, .beta.-OZ.sup.d), or oxygen atom, each of Z.sup.a and Z.sup.d, which may be the same or different, is a hydrogen atom or a protective radical for a hydroxyl radical;U is a radical selected from the group consisting of CR.sup.1 HCH.sub.2, CR.sup.1 .dbd.CH and C.tbd.C,whereinR.sup.1 is a hydrogen atom, halogen atom, substituted silyl radical represented by SiR.sup.9 R.sup.10 R.sup.11 or substituted stannyl radical represented by SnR.sup.14 R.sup.15 R .sup.16,m is an integer of 0 to 6;X.sup.2 is CH.dbd.CH or C.tbd.C,p is an integer of 0 or 1, each of n and q is an integer of 0 to 5; andZ.sup.1 is a hydrogen atom, COOR.sup.y, CN, OH, OCOR.sup.2, CONR.sup.b R.sup.c or NR.sup.d R.sup.e.